Genprex names Thomas C. Gallagher as the company"s senior vice president of Intellectual Property and Licensing – Proactive Investors USA &…

Gallagher has extensive experience in the area of biotechnology intellectual property (IP) law, business development, and licensing transactions with industry and academic institutions

() hasnamed Thomas C. Gallagheras the companys senior vice president of Intellectual Property and Licensing.

The clinical-stage gene therapy company, which is developing potentially life-changing technologies for patients with cancer and diabetes, noted that Gallagher has extensive experience in the area of biotechnology intellectual property (IP) law, business development, and licensing transactions with industry and academic institutions.

In a statement, Rodney Varner, Genprex's president and chief executive officer commented: "Mr Gallagher will play a critical role in advancing our expanding intellectual property estate by spearheading IP strategy, which is an important element of the Companys overall success and value creation. A seasoned biotech executive, he will provide significant support as we execute on broadening our research and development programs, explore opportunities for partnerships on our existing programs, and opportunistically acquire new technologies to further expand our pipeline."

The company noted that Gallagher has more than 20 years of experience as an intellectual property attorney. Prior to joining Genprex, he served as principal at the Fenagh Group, an IP and licensing consultancy providing clients in the healthcare sector guidance on all aspects of patent and trademark portfolio management, intellectual property due diligence, freedom-to-operate analysis and related transactional work.

He has also served as senior vicepresident of Intellectual Property and Licensing at Kadmon Corporation, LLC, a biopharmaceutical company based in Manhattan. Prior to joining Kadmon, he served as in-house IP counsel at Neostem Inc. (now Caladrius Biosciences, Inc.), a company focused on stem cell biology. Previously, he held several positions at ImClone Systems Incorporated, most recently as Vice President of Intellectual Property and Licensing.

While at ImClone, he was responsible for all aspects of intellectual property and led the IP function in multiple due diligence undertakings by major pharmaceutical companies, which resulted in a $2 billion strategic investment, the highest-valued biotech deal ever at the time, and the eventual sale of the company to Eli Lilly and Company for $6.5 billion.

Gallagher is experienced in both patent prosecution and litigation, as well as intellectual property issues relating to business development and licensing matters. His patent litigation experience includes European litigation and opposition proceedings. In addition to a law degree, heholds a Masters degree in molecular biology. Before becoming an attorney,Gallagher worked as a molecular biologist in France, Spain and the United States.

Contact the author at jon.hopkins@proactiveinvestors.com

Continued here:
Genprex names Thomas C. Gallagher as the company"s senior vice president of Intellectual Property and Licensing - Proactive Investors USA &...